These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33115932)

  • 1. Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies
    Ding Y; Shao Y; Na C; Yin JC; Hua H; Tao R; Jiang Y; Hu R; He X; Miao C; Zhu D; Zhang Z
    J Med Genet; 2022 Jan; 59(1):10-17. PubMed ID: 33115932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
    Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C
    Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
    Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
    J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCartaâ„¢ Panel: exploring therapeutic targets.
    Fallet V; Saffroy R; Girard N; Mazieres J; Lantuejoul S; Vieira T; Rouquette I; Thivolet-Bejui F; Ung M; Poulot V; Schlick L; Moro-Sibilot D; Antoine M; Cadranel J; Lemoine A; Wislez M
    Ann Oncol; 2015 Aug; 26(8):1748-53. PubMed ID: 25969368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NGS Analysis Confirms Common
    Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
    Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
    J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.
    Mehrad M; Roy S; LaFramboise WA; Petrosko P; Miller C; Incharoen P; Dacic S
    Histopathology; 2018 Aug; 73(2):207-214. PubMed ID: 29489023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients.
    Liang Z; Zeng G; Wan W; Deng B; Chen C; Li F; Lin G; Lin Y; Lin H; Mo G; Miao H
    Discov Med; 2023 Apr; 35(175):131-143. PubMed ID: 37188510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
    Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
    Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of germline mutations in RB1 in Chinese patients with retinoblastoma: Application of targeted next-generation sequencing.
    Zou Y; Li J; Hua P; Liang T; Ji X; Zhao P
    Mol Vis; 2021; 27():1-16. PubMed ID: 33456302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
    Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.